News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News ESC 2025 ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients Michael O'Riordan September 10, 2025
News Conference News ESC 2025 Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b Caitlin E. Cox August 31, 2025
News Opinion Editor's Corner ESC 2025 What’s Going to Be Hot at ESC Congress 2025? Michael O'Riordan August 25, 2025
News Daily News PREVENT Risk Calculator Works Well in Patients With High and Low Lp(a) Michael O'Riordan June 10, 2025
News Conference News ESC Heart Failure 2025 HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM Todd Neale May 19, 2025
News Daily News Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM Caitlin E. Cox March 21, 2025
News Daily News High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low Michael O'Riordan November 13, 2024
News Daily News Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime Michael O'Riordan October 14, 2024
News Conference News ESC 2024 Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events Caitlin E. Cox August 31, 2024
News Daily News Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE Yael L. Maxwell August 19, 2024
News Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia Michael O'Riordan May 30, 2024
News Daily News Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups Michael O'Riordan April 17, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Daily News High Lp(a) Levels Harmful in Patients With and Without ASCVD Michael O'Riordan February 27, 2024
News Daily News Less Is More: Lp(a) Much More Atherogenic Than LDL Michael O'Riordan January 16, 2024
News Conference News AHA 2023 Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study Michael O'Riordan November 13, 2023